Identification and functional characteristics of CHD1L gene variants implicated in human Müllerian duct anomalies.

Biol Res

Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, 17 QiHeLou Street, Dongcheng District, Beijing, 100006, China.

Published: September 2024

AI Article Synopsis

  • Müllerian duct anomalies (MDAs) are congenital reproductive tract disorders in females, with recent advancements in whole-exome sequencing (WES) providing new insights into their genetic causes, though many mechanisms remain unclear.
  • In a study involving 97 MDAs patients, researchers identified two novel heterozygous CHD1L variants linked to these anomalies, with variants' pathogenicity confirmed through functional assays and molecular simulations.
  • The study found that the identified variants impaired CHD1L function, affecting protein localization and interactions, leading to a calculated contribution of CHD1L variants to MDAs at 4.12%.

Article Abstract

Background: Müllerian duct anomalies (MDAs) are congenital developmental disorders that present as a series of abnormalities within the reproductive tracts of females. Genetic factors are linked to MDAs and recent advancements in whole-exome sequencing (WES) provide innovative perspectives in this field. However, relevant mechanism has only been investigated in a restricted manner without clear elucidation of respective observations.

Methods: Our previous study reported that 2 of 12 patients with MDAs harbored the CHD1L variant c.348-1G>C. Subsequently, an additional 85 MDAs patients were recruited. Variants in CHD1L were screened through the in-house database of WES performed in the cohort and two cases were identified. One presented with partial septate uterus with left renal agenesis and the other with complete septate uterus, duplicated cervices and longitudinal vaginal septum. The pathogenicity of the discovered variants was further assessed by molecular dynamics simulation and various functional assays.

Results: Ultimately, two novel heterozygous CHD1L variants, including a missense variant c.956G>A (p.R319Q) and a nonsense variant c.1831C>T (p.R611*) were observed. The variants were absent in 100 controls. Altogether, the contribution yield of CHD1L to MDAs was calculated as 4.12% (4/97). All three variants were assessed as pathogenic through various functional analysis. The splice-site variant c.348-1G>C resulted in a 11 bp sequence skipping in exon 4 of CHD1L and led to nonsense mediated decay of its transcripts. Unlike WT CHD1L, the truncated R611* protein mislocalized to the cytoplasm, abolish the ability of CHD1L to promote cell migration and failed to interact with PARP1 owing to the loss of macro domain. The R319Q variant exhibited conformational disparities and showed abnormal protein recruitment behavior through laser microirradiation comparing with the WT CHD1L. All these variants impaired the CHD1L function in DNA damage repair, thus participating in MDAs.

Conclusions: The current study not only expands the mutational spectrum of CHD1L in MDAs but determines three variants as pathogenic according to ACMG guidelines with reliable functional evidence. Additionally, the impairment in DNA damage repair is an underlying mechanism involved in MDAs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11437902PMC
http://dx.doi.org/10.1186/s40659-024-00550-wDOI Listing

Publication Analysis

Top Keywords

chd1l
11
variants
8
müllerian duct
8
duct anomalies
8
variant c348-1g>c
8
septate uterus
8
variants assessed
8
chd1l variants
8
chd1l mdas
8
three variants
8

Similar Publications

To investigate CHD1L's impacts and molecular processes in hypoxic cutaneous squamous cell carcinoma. Monoclonal proliferation assays and CCK-8 were used to detect the proliferation capacity of A431 cells and Colon16 cells; wound healing experiments and Transwell assays were used to examine the migration and invasion capacity of A431 cells and Colon16 cells; angiogenesis experiments were conducted to assess the influence of A431 cells on angiogenesis; a nude mouse tumor xenograft experiment and HE staining were utilized to evaluate the impact of CHD1L on the progression of cutaneous squamous cell carcinoma; western blot analysis was performed to detect the expression of p-PI3K, p-AKT, and PD-L1 in A431 cells, as well as CD9, TSG101, PD-L1 in exosomes, and CD206, Arginase-1, iNOS, IL-1β, p-AKT, p-mTOR, VEGF, COX-2, MMP2, MMP9, p-ERK1/2 in tumor-associated macrophages. Under hypoxic conditions, CHD1L promoted the proliferation, migration, invasion, and angiogenesis of cutaneous squamous cell carcinoma.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is one of the most prevalent and deadly forms of cancer. It is universally treated with a combination of the DNA damaging chemotherapy drugs irinotecan, 5-Fluorouracil (5-FU), and oxaliplatin. is a novel oncogene that plays critical roles in chromatin remodeling and DNA damage repair, as well as the regulation of malignant gene expression.

View Article and Find Full Text PDF
Article Synopsis
  • - Epithelial-to-mesenchymal transition (EMT) is a process that helps cancer cells spread (metastasize) and become resistant to cell death and treatments, but the triggers for EMT are not well understood
  • - The study shows that DNA damage activates specific proteins (PARP and ALC1), which help EMT transcription factors access DNA, leading to changes in cell behavior and enhanced ability to repair DNA
  • - Using a PARP inhibitor can reverse or prevent EMT caused by DNA damage, and help make cancer cells more sensitive to other treatments, offering potential new strategies for cancer therapy
View Article and Find Full Text PDF

Targeting ATP catalytic activity of chromodomain helicase CHD1L for the anticancer inhibitor discovery.

Int J Biol Macromol

November 2024

Ganjiang Chinese Medicine Innovation Center, Nanchang 330000, China; CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. Electronic address:

Article Synopsis
  • - CHD1L is an enzyme that plays a significant role in cancer progression, particularly in drug resistance and changes in cell behavior (epithelial-mesenchymal transition), making it a valuable target for new cancer treatments.
  • - Researchers used a combination of deep learning and lab experiments to screen over 1.5 million small molecules and identified 36 potential inhibitors of CHD1L, focusing on 13 of these for further evaluation.
  • - The compound C071-0684 was found to be an effective anticancer agent, particularly against colorectal and breast cancer, demonstrating strong binding and activity against CHD1L, indicating its potential for future cancer therapies.
View Article and Find Full Text PDF

Identification and functional characteristics of CHD1L gene variants implicated in human Müllerian duct anomalies.

Biol Res

September 2024

Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, 17 QiHeLou Street, Dongcheng District, Beijing, 100006, China.

Article Synopsis
  • Müllerian duct anomalies (MDAs) are congenital reproductive tract disorders in females, with recent advancements in whole-exome sequencing (WES) providing new insights into their genetic causes, though many mechanisms remain unclear.
  • In a study involving 97 MDAs patients, researchers identified two novel heterozygous CHD1L variants linked to these anomalies, with variants' pathogenicity confirmed through functional assays and molecular simulations.
  • The study found that the identified variants impaired CHD1L function, affecting protein localization and interactions, leading to a calculated contribution of CHD1L variants to MDAs at 4.12%.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!